Name
University of Phoenix
NSG/508 Theoretical Foundations of Advanced Nursing Practice
Prof. Name
Date
Mild persistent asthma in adolescents is managed with anti-inflammatory asthma therapy, an appropriate reliever strategy, regular monitoring, and education on trigger avoidance and inhaler technique. Treatment should be individualized according to symptom frequency, exacerbation risk, adherence, and response to therapy. For adolescents with persistent asthma, inhaled corticosteroid (ICS)-containing treatment is central to reducing airway inflammation and the risk of exacerbations. Management of coexisting allergic rhinitis, a written asthma action plan, and continued participation in physical activity are also important components of long-term care.
Asthma is a chronic respiratory condition characterized by variable respiratory symptoms and fluctuating expiratory airflow limitation. Airway inflammation and bronchial hyperresponsiveness can cause episodes of wheezing, coughing, chest tightness, and shortness of breath.
In adolescents, asthma symptoms may become particularly noticeable during exercise, exposure to allergens, respiratory infections, or changes in weather. Symptoms can also interfere with sleep, school attendance, sports, and other daily activities.
A typical adolescent with mild persistent asthma may experience:
Coughing or wheezing more than twice a week
Shortness of breath during physical activity
Nighttime cough or awakening
Chest tightness
Exercise-related breathing difficulty
Intermittent need for a reliever inhaler
Symptoms associated with allergens such as pollen, dust mites, or animal dander
A personal or family history of asthma, eczema, or allergic rhinitis can increase the likelihood of an allergic component.
Asthma diagnosis requires more than identifying occasional wheezing. Healthcare professionals combine the patient’s symptom pattern with objective evidence of variable expiratory airflow limitation when possible.
Assessment generally includes a detailed history, physical examination, and pulmonary function testing.
Important areas of assessment include:
Frequency and severity of daytime symptoms
Nighttime awakenings
Exercise limitations
Reliever medication use
Previous asthma exacerbations
Emergency department visits or hospitalizations
Environmental and occupational exposures
Allergic conditions
Medication adherence
Inhaler technique
Family history of asthma or other atopic conditions
Spirometry is commonly used to support the diagnosis and assess lung function. Peak expiratory flow may also be useful for selected patients, particularly when incorporated into an individualized asthma management plan.
During symptomatic periods, an adolescent may have expiratory wheezing, coughing, tachypnea, prolonged expiration, or decreased airflow. Physical examination may be normal between episodes because asthma symptoms and airflow limitation can vary over time.
When allergic rhinitis is present, examination may show nasal congestion, pale or swollen nasal mucosa, rhinorrhea, or itchy and watery eyes.
Persistent or worsening symptoms should prompt reassessment of the diagnosis, treatment adherence, inhaler technique, environmental exposures, and possible comorbid conditions.
The main goals of asthma treatment are to achieve good symptom control while reducing future risks such as severe exacerbations, declining lung function, and treatment-related adverse effects.
Effective asthma management aims to help adolescents:
Sleep without asthma-related symptoms
Participate normally in school and physical activities
Exercise without significant respiratory limitation
Minimize daytime symptoms
Reduce the need for reliever medication
Prevent severe asthma attacks
Maintain the best possible lung function
Avoid unnecessary emergency department visits and hospitalizations
Use medications correctly and consistently
Develop confidence in managing asthma independently
Because adolescence is an important period for developing self-management skills, healthcare professionals should gradually involve the adolescent in medication decisions, symptom monitoring, and recognition of worsening asthma.
For adolescents with persistent asthma, treatment should include an ICS-containing regimen to reduce airway inflammation and lower the risk of exacerbations. The exact regimen depends on the guideline being followed, symptom pattern, risk factors, and clinical assessment.
Current GINA guidance favors ICS-containing therapy rather than treatment with a short-acting beta₂-agonist (SABA) alone. For adolescents and adults with mild asthma, an as-needed low-dose ICS-formoterol approach is preferred in the GINA Track 1 strategy when available and appropriate. Other treatment pathways may use daily low-dose ICS with a reliever.
Therefore, treatment should not be selected solely on the label “mild persistent asthma.” Clinicians should consider the individual’s current symptoms, exacerbation history, medication access, adherence, inhaler technique, and applicable national guidelines.
Inhaled corticosteroids are important controller medications because they directly address the airway inflammation underlying asthma.
Common ICS medications include:
Budesonide
Fluticasone
Beclomethasone
Mometasone
Regular use of prescribed ICS-containing treatment can reduce asthma symptoms, improve lung function, and decrease the likelihood of severe exacerbations.
Adolescents should understand that controller therapy is different from medication used for immediate symptom relief. The purpose of anti-inflammatory therapy is to control the underlying disease rather than simply relieve symptoms after they occur.
Short-acting beta₂-agonists such as albuterol can rapidly relax bronchial smooth muscle and provide short-term relief of bronchoconstriction.
However, SABA-only treatment is not recommended as the sole asthma treatment in current GINA guidance for adolescents and adults. Overreliance on SABA can leave airway inflammation untreated and is associated with an increased risk of asthma exacerbations.
When SABA is prescribed as part of an appropriate treatment plan, excessive use should prompt clinical reassessment. Increasing reliance on a reliever medication may indicate inadequate control, poor adherence, incorrect inhaler technique, or the need to modify controller therapy.
Asthma should not prevent adolescents from participating in sports or regular physical activity. With appropriate management, most young people with asthma can participate fully in exercise, including competitive athletics.
For adolescents who develop exercise-induced bronchoconstriction, healthcare professionals may recommend an appropriate pre-exercise reliever strategy. Warm-up activities, adequate baseline asthma control, and avoidance of known triggers can also help reduce exercise-related symptoms.
Persistent exercise limitation despite treatment should be evaluated rather than accepted as an unavoidable consequence of asthma.
Allergic rhinitis commonly occurs alongside asthma because both conditions involve inflammation of the respiratory tract. Poorly controlled upper-airway symptoms can contribute to respiratory symptoms and make asthma more difficult to manage.
Management may include:
Intranasal corticosteroids for persistent allergic nasal symptoms
Second-generation antihistamines when appropriate
Environmental allergen reduction
Allergy evaluation when clinically indicated
Allergen immunotherapy for carefully selected patients
Other conditions that can affect asthma control should also be considered, including obesity, gastroesophageal reflux, dysfunctional breathing, anxiety, and chronic sinus or nasal disease.
Education is a major part of adolescent asthma care. A treatment plan is less effective when a patient does not understand how or when to use the prescribed medication.
Education should cover:
Correct inhaler and spacer technique when applicable
Difference between controller and reliever medications
Recognition of early worsening symptoms
Medication adherence
Trigger identification and avoidance
Use of a written asthma action plan
When to contact a healthcare professional
When emergency care is necessary
Healthcare professionals should use teach-back techniques to confirm that the adolescent can demonstrate correct inhaler use and explain the action plan.
Asthma triggers differ between individuals, so environmental recommendations should be individualized rather than unnecessarily restrictive.
Potential triggers include tobacco smoke, indoor allergens, pollen, mold, respiratory infections, air pollution, strong odors, and occupational or chemical exposures.
Helpful measures may include controlling indoor moisture and mold, avoiding tobacco smoke, reducing exposure to known allergens, and checking air-quality or pollen information when outdoor triggers are important.
Environmental interventions are most useful when they target triggers that are actually relevant to the individual adolescent.
Asthma is a variable disease, so treatment should be reviewed periodically rather than treated as a one-time intervention.
Follow-up should evaluate both current symptom control and future risk.
Healthcare professionals may assess:
Daytime symptoms
Nighttime awakenings
Activity limitation
Reliever use
Exacerbations
Lung function
Medication adherence
Inhaler technique
Exposure to triggers
Adverse medication effects
School and sports participation
After initiating or changing treatment, follow-up is commonly performed within approximately 1–3 months, depending on the clinical situation. Once asthma is stable, periodic reassessment remains important.
If asthma is poorly controlled, clinicians should first determine whether the problem is caused by incorrect inhaler technique, poor adherence, ongoing exposure, an incorrect diagnosis, or untreated comorbidities before simply increasing medication.
Asthma treatment should follow a stepwise approach. When symptoms remain uncontrolled, therapy may need to be intensified after modifiable factors have been addressed.
Conversely, treatment may be reduced when asthma has remained well controlled for an appropriate period and the clinician determines that stepping down is safe.
Medication changes should be made under clinical supervision. Adolescents should not independently stop their controller therapy simply because they feel better.
Adolescence introduces unique challenges to asthma management. Young people may forget medications, resist treatment because of social concerns, or avoid carrying inhalers because they feel embarrassed.
Healthcare professionals should use age-appropriate education and involve adolescents in their own care. Discussions should address school activities, sports, medication access, peer concerns, family support, and barriers to adherence.
Parents and caregivers should remain involved when appropriate while allowing the adolescent to develop increasing independence.
Mild persistent asthma in adolescents requires more than treating symptoms when they occur. ICS-containing therapy, appropriate reliever treatment, regular assessment, education, and management of triggers and comorbidities form the foundation of effective asthma care.
Important points include:
Persistent asthma requires an anti-inflammatory treatment strategy.
Current GINA guidance recommends against SABA-only treatment for adolescents and adults.
Inhaler technique and adherence should be checked before escalating therapy.
Allergic rhinitis should be identified and treated when present.
Most adolescents with well-controlled asthma can safely participate in sports.
A written asthma action plan helps patients recognize and respond to worsening symptoms.
Increasing reliever use or recurrent exacerbations should trigger reassessment.
Treatment should be individualized and adjusted using a stepwise approach.
The appropriate first-line strategy is ICS-containing asthma therapy. Current GINA guidance prefers an as-needed low-dose ICS-formoterol strategy for adolescents and adults with mild asthma when available and appropriate. Daily low-dose ICS with an appropriate reliever remains another guideline-supported approach in certain circumstances.
The important principle is that adolescents with persistent asthma should receive treatment that addresses airway inflammation rather than relying on a SABA alone.
Allergic rhinitis and asthma frequently occur together and share inflammatory pathways. Identifying and treating allergic rhinitis can improve overall respiratory symptom control and reduce factors that contribute to poor asthma control.
After starting or changing treatment, follow-up is generally appropriate within 1–3 months, although the exact timing depends on severity and clinical circumstances. Once asthma is controlled, periodic reassessment should continue, with the interval individualized according to symptoms and risk.
Yes. Well-controlled asthma should not prevent adolescents from participating in sports or other physical activities. Appropriate long-term asthma management and an individualized plan for exercise-related symptoms can help adolescents remain active.
Depending on the individualized asthma plan, adolescents may monitor:
Daytime symptoms
Nighttime symptoms
Reliever medication use
Exercise tolerance
Peak flow measurements when specifically recommended
Exposure to known triggers
Early signs of worsening asthma
A written asthma action plan should explain what steps to take when symptoms begin to worsen.
Traditionally, asthma severity classifications describe mild persistent asthma as symptoms occurring more than twice weekly but not every day, with nighttime symptoms occurring several times per month. However, modern asthma guidelines increasingly emphasize level of symptom control and future exacerbation risk rather than relying solely on severity labels.
When prescribed at appropriate doses and used correctly, inhaled corticosteroids have a well-established safety profile and provide important benefits by reducing airway inflammation and exacerbation risk. Clinicians should use the lowest effective dose needed to maintain control and monitor for potential adverse effects.
Frequent reliance on a rescue inhaler can indicate inadequate asthma control and should prompt reassessment. Adolescents should follow the specific reliever strategy prescribed by their healthcare professional rather than increasing medication use independently.
Asthma symptoms can change over time, and some children and adolescents experience periods of reduced symptoms. However, symptom improvement does not necessarily mean that asthma has permanently resolved. Continued assessment is important because symptoms can recur.
Treatment should be reassessed when symptoms become more frequent, nighttime awakenings increase, activity becomes limited, reliever use increases, lung function worsens, or an exacerbation occurs. Before stepping up therapy, clinicians should review adherence, inhaler technique, environmental exposures, comorbidities, and the accuracy of the diagnosis.
Emergency evaluation is appropriate when asthma symptoms become severe or rapidly worsen, the adolescent has significant difficulty breathing, cannot speak normally because of breathlessness, develops severe chest tightness, becomes unusually drowsy or confused, or does not respond adequately to the prescribed reliever according to the asthma action plan.
Asthma management in adolescents should be individualized and based on current evidence-based guidelines. The central principle is to use ICS-containing therapy to reduce airway inflammation and exacerbation risk, while providing an appropriate reliever strategy for symptoms. Regular follow-up, correct inhaler technique, adherence, trigger management, treatment of allergic rhinitis, and a written asthma action plan can help adolescents maintain good control and participate fully in school, sports, and everyday activities.
Global Initiative for Asthma. (2025). Global strategy for asthma management and prevention. https://ginasthma.org/
National Heart, Lung, and Blood Institute. (2020). 2020 focused updates to the asthma management guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. National Institutes of Health. https://www.nhlbi.nih.gov/resources/2020-focused-updates-asthma-management-guidelines
National Heart, Lung, and Blood Institute. (n.d.). Asthma. https://www.nhlbi.nih.gov/health/asthma
Cloutier, M. M., Baptist, A. P., Blake, K. V., Brooks, E. G., Bryant-Stevens, T., DiMango, E., Dixon, A. E., Elward, K. S., Hartert, T., Krishnan, J. A., Lemanske, R. F., Ouellette, D. R., Pace, W., Schatz, M., Skolnik, N. S., Stout, J. W., & Williams, P. V. (2020). 2020 focused updates to the asthma management guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Journal of Allergy and Clinical Immunology, 146(6), 1217–1270. https://doi.org/10.1016/j.jaci.2020.10.003
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., Inoue, H., Ko, F. W. S., Krishnan, J. A., Levy, M. L., Lin, J., Mortimer, K., Pitrez, P. M., Sheikh, A., Yorgancioglu, A., & Boulet, L.-P. (2022). Global Initiative for Asthma strategy 2021: Executive summary and rationale for key changes. American Journal of Respiratory and Critical Care Medicine, 205(1), 17–35. https://doi.org/10.1164/rccm.202109-2205PP
